PH30430A - Method for lowering serum cholesterol - Google Patents

Method for lowering serum cholesterol

Info

Publication number: PH30430A
Authority: PH; Philippines
Prior art keywords: alkanoyloxy; substituted; unsubstituted; serum cholesterol; lowering serum
Prior art date: 1992-12-22

Application number

PH47481A

Other languages

English (en)

Inventor

Larry John Cullinan Geor Black

Henry Uhlman Bryant

Raymond Francis Kauffman

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-22

Filing date

1993-12-17

Publication date

1997-05-09

1993-12-17 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1997-05-09 Publication of PH30430A publication Critical patent/PH30430A/en

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 2
125000004423 acyloxy group Chemical group 0.000 abstract 4
-1 chloro, bromo, methoxy Chemical group 0.000 abstract 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
125000005333 aroyloxy group Chemical group 0.000 abstract 2
125000005200 aryloxy carbonyloxy group Chemical group 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
241001465754 Metazoa Species 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Bipolar Transistors (AREA)
Semiconductor Lasers (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PH47481A 1992-12-22 1993-12-17 Method for lowering serum cholesterol PH30430A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US99522292A	1992-12-22	1992-12-22

Publications (1)

Publication Number	Publication Date
PH30430A true PH30430A (en)	1997-05-09

Family

ID=25541537

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH47481A PH30430A (en)	1992-12-22	1993-12-17	Method for lowering serum cholesterol

Country Status (28)

Country	Link
US (1)	US5464845A (pl)
EP (2)	EP0605193B1 (pl)
JP (1)	JP3197129B2 (pl)
KR (1)	KR100278946B1 (pl)
CN (1)	CN1043608C (pl)
AT (1)	ATE233559T1 (pl)
AU (1)	AU669235B2 (pl)
BG (1)	BG61524B1 (pl)
BR (1)	BR9305182A (pl)
CA (1)	CA2112017C (pl)
CZ (1)	CZ283863B6 (pl)
DE (1)	DE69332735T2 (pl)
DK (1)	DK0605193T3 (pl)
ES (1)	ES2193142T3 (pl)
HU (1)	HU223342B1 (pl)
IL (1)	IL108042A (pl)
MY (1)	MY109345A (pl)
NO (1)	NO304924B1 (pl)
NZ (1)	NZ250486A (pl)
PH (1)	PH30430A (pl)
PL (1)	PL177349B1 (pl)
RO (1)	RO113806B1 (pl)
RU (1)	RU2123335C1 (pl)
SG (1)	SG52696A1 (pl)
SK (1)	SK279271B6 (pl)
TW (1)	TW383306B (pl)
YU (1)	YU48918B (pl)
ZA (1)	ZA939427B (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE38968E1 (en)	1992-07-28	2006-02-07	Eli Lilly And Company	Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) *	1992-07-28	1999-08-11	Lilly Co Eli	The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE39049E1 (en)	1992-07-28	2006-03-28	Eli Lilly And Company	Methods for inhibiting bone loss
US5482949A (en) *	1993-03-19	1996-01-09	Eli Lilly And Company	Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5482950A (en) *	1993-10-15	1996-01-09	Eli Lilly And Company	Methods for lowering serum cholesterol
US6489355B2 (en) *	1993-12-01	2002-12-03	Eli Lilly And Company	Methods of inhibiting the effects of amyloidogenic proteins
ZA949715B (en) *	1993-12-14	1996-06-06	Lilly Co Eli	Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins and pharmaceutical formulations and methods thereof
EP0963756B1 (en) *	1993-12-21	2004-02-25	Eli Lilly And Company	Inhibition of advanced glycosylation end products
US5441966A (en) *	1993-12-21	1995-08-15	Eli Lilly And Company	Methods of inhibiting Turner's syndrome
US6417198B1 (en)	1993-12-21	2002-07-09	Eli Lilly And Company	Methods of inhibiting CNS problems in post-menopausal women
US5478847A (en) *	1994-03-02	1995-12-26	Eli Lilly And Company	Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es)	1994-09-19	1997-01-09	Lilly Co Eli	3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US5629425A (en) *	1994-09-19	1997-05-13	Eli Lilly And Company	Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
EP0895781A3 (en) *	1994-10-20	1999-07-07	Eli Lilly And Company	Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins
US6562862B1 (en) *	1994-10-20	2003-05-13	Eli Lilly And Company	Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5552412A (en)	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5484808A (en) *	1995-02-09	1996-01-16	Eli Lilly And Company	Methods of inhibiting cell-cell adhesion
JPH11504013A (ja) *	1995-04-21	1999-04-06	イーライ・リリー・アンド・カンパニー	新規な塩基性側鎖を有するベンゾチオフェン
CA2223595C (en) *	1995-06-07	2008-08-05	Neorx Corporation	Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5731328A (en) *	1995-10-10	1998-03-24	Eli Lilly And Company	Methods of inhibiting plasminogen activator inhibitor 1
US5726168A (en) *	1995-10-12	1998-03-10	Eli Lilly And Company	Lipophilic benzothiophenes
HN1996000101A (es)	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis
IL120266A (en) *	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) *	1996-02-28	2001-06-23	Pfizer	New therapeutic uses of estrogen agonists
EP0801066A1 (en) *	1996-03-12	1997-10-15	Eli Lilly And Company	Heterocyclic substituted benzothiophenes and pharmaceutical compositions
WO1997034888A1 (en) *	1996-03-19	1997-09-25	Eli Lilly And Company	SYNTHESIS OF 3-[4-(2-AMINOETHOXY)-BENZOYL]-2-ARYL-6-HYDROXY-BENZO[b]THIOPHENES
US6458811B1 (en)	1996-03-26	2002-10-01	Eli Lilly And Company	Benzothiophenes formulations containing same and methods
US5811437A (en) *	1996-05-21	1998-09-22	Eli Lilly And Company	Methods of increasing nitric oxide synthesis
US5747509A (en) *	1996-06-03	1998-05-05	Schering Aktiengesellschaft	Method for lowering plasma levels of lipoprotein(a)
CA2206752A1 (en) *	1996-07-02	1998-01-02	George Joseph Cullinan	Benzothiophene compounds, intermediates, processes, and methods of use
US5980938A (en) *	1996-07-15	1999-11-09	Eli Lilly And Company	Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
CA2214072C (en) *	1996-08-29	2006-11-14	Eli Lilly And Company	Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
US5773432A (en) *	1996-10-30	1998-06-30	Schering Aktiengesellschaft	Method for lowering plasma levels of lipoprotein(a)
UA59384C2 (uk)	1996-12-20	2003-09-15	Пфайзер, Інк.	Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
CA2236254A1 (en) *	1997-04-30	1998-10-30	David Warren Hoard	Process for preparing benzo¬b\|thiophenes
KR20010020378A (ko) *	1997-04-30	2001-03-15	피터 지. 스트링거	벤조티오펜의 제조 방법
JP2001523253A (ja) *	1997-04-30	2001-11-20	イーライ・リリー・アンド・カンパニー	ベンゾ［ｂ］チオフェン類の製造のための中間体および方法
CA2231013A1 (en) *	1997-04-30	1998-10-30	Eli Lilly And Company	Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
JP2001524114A (ja) *	1997-04-30	2001-11-27	イーライ・リリー・アンド・カンパニー	ベンゾ［ｂ］チオフェン類の製造における中間体および方法
CA2287918A1 (en) *	1997-04-30	1998-11-05	John Mcneill Mcgill Iii	A regioselective alkylation process for preparing substituted benzo¬b\|thiophenes
US6124314A (en) *	1997-10-10	2000-09-26	Pfizer Inc.	Osteoporosis compounds
US6096781A (en) *	1997-11-14	2000-08-01	Eli Lilly And Company	2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US6465445B1 (en)	1998-06-11	2002-10-15	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en)	1998-06-11	2006-02-28	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6353003B1 (en)	1998-06-17	2002-03-05	Eli Lilly And Company	Method for reducing levels of homocysteine and C-reactive protein
US6258826B1 (en)	1998-10-13	2001-07-10	Eli Lilly And Company	Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
RU2233162C2 (ru) *	1999-02-06	2004-07-27	Астразенека Аб	Лекарственные комбинации, включающие (е)-7-[-4-(4-фторфенил)-6-изопропил-2-[-метил(метилсульфонил)амино]- пиримидин-5-ил](3r,5s)-3,5-дигидроксигепт-6-еноевую кислоту и ингибитор, индуктор или субстрат изофермента р450-3а4
AP2001002357A0 (en)	1999-12-22	2001-12-31	Pfizer Prod Inc	EP4 receptor selective agonists in the treatment of osteoporosis.
DE60124616T2 (de) *	2000-05-08	2007-09-13	Pfizer Products Inc., Groton	Enzymatische Spaltung von selektiven Modulatoren des Östrogenrezeptors
US20030216358A1 (en) *	2001-07-05	2003-11-20	Muchmore Douglas Boyer	Method for enhancing bone mineral density gain
SG162615A1 (en) *	2002-06-13	2010-07-29	Wyeth Corp	Bazedoxifene treatment regimens
US20060106010A1 (en) *	2003-05-27	2006-05-18	Black Larry J	Methods for inhibiting bone loss
US20070191319A1 (en) *	2003-12-17	2007-08-16	Pfizer Inc.	Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
EP2173648A4 (en)	2007-07-27	2012-11-21	Container Stuffers Llc	FREIGHT LOADER
CN101669557B (zh) *	2009-08-20	2012-07-25	杭州六易科技有限公司	一种清热解毒凉茶的制作方法
WO2016021706A1 (ja) *	2014-08-08	2016-02-11	カズマパートナーズ株式会社	縮合複素環化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
ES541839A0 (es) *	1983-06-24	1985-12-01	Yamanouchi Pharma Co Ltd	Un procedimiento para la preparacion de un derivado de feno-xialquilester
EP0166025A3 (en) *	1984-06-27	1986-08-20	American Cyanamid Company	Non-antibiotic animal feed additive compositions
US4729999A (en) *	1984-10-12	1988-03-08	Bcm Technologies	Antiestrogen therapy for symptoms of estrogen deficiency
AT391316B (de) *	1988-09-15	1990-09-25	Ebewe Arzneimittel	Neue thienyloxy-alkylamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW366342B (en) *	1992-07-28	1999-08-11	Lilly Co Eli	The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5441964A (en) *	1993-10-15	1995-08-15	Eli Lilly And Company	Methods for inhibiting bone loss using substituted benzothiophene

1993
- 1993-02-04 TW TW082100751A patent/TW383306B/zh not_active IP Right Cessation
- 1993-11-30 US US08/159,159 patent/US5464845A/en not_active Expired - Fee Related
- 1993-12-13 RU RU93055026A patent/RU2123335C1/ru not_active IP Right Cessation
- 1993-12-15 SK SK1421-93A patent/SK279271B6/sk unknown
- 1993-12-15 MY MYPI93002719A patent/MY109345A/en unknown
- 1993-12-15 ZA ZA939427A patent/ZA939427B/xx unknown
- 1993-12-16 NZ NZ250486A patent/NZ250486A/en active IP Right Revival
- 1993-12-16 IL IL108042A patent/IL108042A/en not_active IP Right Cessation
- 1993-12-16 CZ CZ932790A patent/CZ283863B6/cs not_active IP Right Cessation
- 1993-12-17 PH PH47481A patent/PH30430A/en unknown
- 1993-12-20 YU YU79893A patent/YU48918B/sh unknown
- 1993-12-20 RO RO93-01739A patent/RO113806B1/ro unknown
- 1993-12-20 HU HU9303676A patent/HU223342B1/hu not_active IP Right Cessation
- 1993-12-20 PL PL93301579A patent/PL177349B1/pl not_active IP Right Cessation
- 1993-12-21 BR BR9305182A patent/BR9305182A/pt not_active Application Discontinuation
- 1993-12-21 NO NO934740A patent/NO304924B1/no unknown
- 1993-12-21 AU AU52578/93A patent/AU669235B2/en not_active Ceased
- 1993-12-21 CA CA002112017A patent/CA2112017C/en not_active Expired - Fee Related
- 1993-12-21 KR KR1019930028895A patent/KR100278946B1/ko not_active Expired - Fee Related
- 1993-12-21 BG BG98317A patent/BG61524B1/bg unknown
- 1993-12-22 EP EP93310438A patent/EP0605193B1/en not_active Expired - Lifetime
- 1993-12-22 SG SG1996008021A patent/SG52696A1/en unknown
- 1993-12-22 CN CN93121277A patent/CN1043608C/zh not_active Expired - Fee Related
- 1993-12-22 EP EP02013421A patent/EP1238667A3/en not_active Withdrawn
- 1993-12-22 JP JP32382593A patent/JP3197129B2/ja not_active Expired - Fee Related
- 1993-12-22 AT AT93310438T patent/ATE233559T1/de not_active IP Right Cessation
- 1993-12-22 DK DK93310438T patent/DK0605193T3/da active
- 1993-12-22 DE DE69332735T patent/DE69332735T2/de not_active Expired - Fee Related
- 1993-12-22 ES ES93310438T patent/ES2193142T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2112017A1 (en)	1994-06-23
YU48918B (sh)	2002-11-15
JP3197129B2 (ja)	2001-08-13
DE69332735T2 (de)	2003-10-23
SK142193A3 (en)	1995-01-12
CZ283863B6 (cs)	1998-06-17
CN1094042A (zh)	1994-10-26
PL301579A1 (en)	1994-06-27
IL108042A (en)	1998-01-04
BG61524B1 (bg)	1997-11-28
EP1238667A3 (en)	2003-12-10
PL177349B1 (pl)	1999-10-29
MY109345A (en)	1997-01-31
NO304924B1 (no)	1999-03-08
AU669235B2 (en)	1996-05-30
NO934740L (no)	1994-06-23
DK0605193T3 (da)	2003-03-31
EP0605193B1 (en)	2003-03-05
HU9303676D0 (en)	1994-04-28
TW383306B (en)	2000-03-01
CZ279093A3 (en)	1994-07-13
US5464845A (en)	1995-11-07
YU79893A (sh)	1997-05-28
CA2112017C (en)	2005-06-14
ES2193142T3 (es)	2003-11-01
RU2123335C1 (ru)	1998-12-20
BG98317A (en)	1995-02-28
KR940013501A (ko)	1994-07-15
HU223342B1 (hu)	2004-06-28
JPH06234632A (ja)	1994-08-23
ZA939427B (en)	1995-06-15
NO934740D0 (no)	1993-12-21
BR9305182A (pt)	1994-08-16
SK279271B6 (sk)	1998-08-05
HUT69686A (en)	1995-09-28
KR100278946B1 (ko)	2001-01-15
EP1238667A2 (en)	2002-09-11
CN1043608C (zh)	1999-06-16
DE69332735D1 (de)	2003-04-10
RO113806B1 (ro)	1998-11-30
IL108042A0 (en)	1994-04-12
ATE233559T1 (de)	2003-03-15
SG52696A1 (en)	1998-09-28
EP0605193A1 (en)	1994-07-06
AU5257893A (en)	1994-07-07
NZ250486A (en)	1997-06-24

Publication	Publication Date	Title
PH30430A (en)	1997-05-09	Method for lowering serum cholesterol
PL309874A1 (en)	1996-02-05	Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives
AU8156394A (en)	1995-06-29	Methods for inhibiting LDL oxidation and atheroclerosis
EP0436734A4 (en)	1992-01-02	New aminopiperazine derivatives
HUT74015A (en)	1996-10-28	Method of lowering serum cholesterol levels with 2,6-dialkyl-4-silyl-phenols
AU543677B2 (en)	1985-04-26	5,10-dihyro-11h-dibenzo(b,e)(1,4)diazepine-11-ones
KR960009425B1 (en)	1996-07-19	Novel diphenylthiazole derivative
AU625238B2 (en)	1992-07-02	Anti-psychotic piperidylbenzimidazole compounds
PL299541A1 (en)	1994-01-10	Novel derivatives of n-[(4-aminocarbonylopyrimidino-2)-aminoalkyl]-2-aminopyrimidine carrbonamide-4, method of obtaining them, drug and pharmaceutical preparation
NO20000750D0 (no)	2000-02-15	Fremgangsmåte for å redusere blodplatetall
HUT64345A (en)	1993-12-28	Methods for producing amino-alkyl-pyrrolidinyl-thio-carbapeneme derivatives and pharmaceutical preparatives containing them as active agent
PH18574A (en)	1985-08-12	Substituted 11-oxo-11h-pyrido 2,i-h -quinazoline derivatives,pharmaceutical compositions containing them and method of use thereof
AU6703090A (en)	1991-06-06	New substituted benzothiazolinones, process for preparing these and pharmaceutical compositions containing them
JPS6426559A (en)	1989-01-27	Novel phthalide derivative
BG95629A (en)	1994-03-31	Derivatives of 10, 11, 12, 13 - tetrahytdrodesmicozine, method for preparing them, and their use as pharmaceutical preparations
JPS5430166A (en)	1979-03-06	2-aminomethyl-5-phenyloxazoles and their pharmaceutically acceptable acid salts